Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of CT-L01 (Nesina Met XR) vs Co-administered Alogliptin and Metformin XR in Healthy Volunteers
NCT05363384Phase 1Completed
- Sponsor
- Celltrion
- Start
- Jun 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CT-L01 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Celltrion. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration at 72 hours and Peak Plasma Concentration at 72 hours. Started Jun 2022; status: completed.
02
Drugs
CT-L01
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05363384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363384.